Targeting autophagy in disease: established and new strategies
Muhammed Koçak(Institute of Cancer Research), Ole Pleß(Fraunhofer Institute for Translational Medicine and Pharmacology), Inés Maestro(Centro de Investigaciones Biológicas Margarita Salas), Saba Ezazi Erdi(Fraunhofer Institute for Translational Medicine and Pharmacology), Guillem Jorba(Anaxomics (Spain)), Vladimir Kirkin(Molecular Partners (Switzerland)), Judith Farrés(Anaxomics (Spain)), Ana Martı́nez(Consejo Superior de Investigaciones Científicas)
Cited by 229
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293